2.16
-0.02(-0.92%)
Currency In USD
| Previous Close | 2.18 |
| Open | 2.18 |
| Day High | 2.2 |
| Day Low | 2.09 |
| 52-Week High | 9.79 |
| 52-Week Low | 0.97 |
| Volume | 56,776 |
| Average Volume | 1.15M |
| Market Cap | 10.36M |
| PE | -0.24 |
| EPS | -9.02 |
| Moving Average 50 Days | 2.4 |
| Moving Average 200 Days | 2.17 |
| Change | -0.02 |
If you invested $1000 in Phio Pharmaceuticals Corp. (PHIO) 10 years ago, it would be worth $0.01 as of August 18, 2025 at a share price of $2.16. Whereas If you bought $1000 worth of Phio Pharmaceuticals Corp. (PHIO) shares 5 years ago, it would be worth $7.94 as of August 18, 2025 at a share price of $2.16.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Newsfile
Aug 14, 2025 8:15 PM GMT
Clinical trial advances for INSTASYL siRNA lead product candidate PH-7625th cohort enrolling patients in on-going clinical studyKing of Prussia, Pennsylvania--(Newsfile Corp. - August 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinica
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds
Newsfile
Jul 25, 2025 7:04 PM GMT
King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminat
Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort
Newsfile
Jul 25, 2025 4:36 PM GMT
Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4 metastatic Merkel cell patientKing of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is